Phosphate requirement for anaerobic fixed film treatment of landfill leachate

1988 ◽  
Vol 15 (3) ◽  
pp. 334-347 ◽  
Author(s):  
Dhandapani Thirumurthi ◽  
Glenn Robert Groskopf

Three laboratory model anaerobic fixed film reactors, AFFR-A, B, and C, fed by a pretreated leachate, were monitored at 35 ± 5 °C for 10 months to estimate the effects of different concentrations and the forms of phosphate (ortho, organic, or condensed) on performances at 1.2–1.8 g COD/(d∙L) of reactor volume. Ortho phosphate (Na3PO4) supplement was added to the feed of AFFR-A, organic phosphate (sodium glycerophosphate: C3H7Na2O6P∙5H2O) to AFFR-B, and condensed phosphate (Na4P2O7) to AFFR-C at a feed COD/P value of about 6100 for 23 weeks (Phase I). When no PO4 deficiency was observed, the value was increased to 7700 in reactors A and B, but the PO4 supplement was terminated for reactor C, resulting in a value of 64 300 (Phase II). The average COD of C effluent was 599 mg/L as compared to 451 and 442 mg/L for reactors A and B, respectively, suggesting that a COD/P of 64 300 was too high. During Phase III, the COD/P ratios were changed in reactors A, B, and C, respectively, to 10 200, 15 200, and 34 300. The results indicate that the "optimal" ratio of COD/P lies perhaps between 15 000 and 34 300. Anaerobes did not prefer any one form of PO4 over the other two. Key words: anaerobic treatment, phosphate requirement, ortho phosphate, condensed phosphate, organic phosphate, leachate treatment, fixed film reactor.

1986 ◽  
Vol 17 (3) ◽  
pp. 175-187 ◽  
Author(s):  
M.F. Hamoda ◽  
K.J. Kennedy

1992 ◽  
Vol 25 (7) ◽  
pp. 223-235 ◽  
Author(s):  
H. Macarie ◽  
A. Noyola ◽  
J. P. Guyot

Anaerobic treatment of terephthalic acid plant wastewater was tested using two UASB reactors (T and U) and a downflow tubular fixed film reactor. UASB T was inoculated with sludge sampled from an anaerobic stabilization pond receiving waste activated sludge from a petrochemical industry treatment plant. UASB U and the fixed film reactor were inoculated with anaerobically adapted activated sludge from a municipal plant. Raw effluent had to be settled and neutralized before reactor feeding. Sedimentation resulted in 70% TSS and 37% COD removal. UASB digesters presented comparable treatment efficiencies with rather low COD removals: the best results were 46.4% for UASB T at 2.6 kg COD/m3.d and a hydraulic retention time (θ) of 2.7 days and 43.9% for UASB U at 2.2 kg COD/m3.d and θ of 3.2 days. The performance of the tubular reactor was much higher, 74.5% COD removal at 1.89 kg/m3.d and θ of 3.4 days. The better efficiencies of this last digester are explained mainly by a higher VSS content and a better resistance to toxicity caused by the aromatics present in the wastewater. A primary settling-anaerobic-aerobic process is proposed as an alternative to the conventional aerobic process for treating terephthalic wastewater, but disposal of solids from primary sedimentation and cost of neutralization have to be considered before application.


1988 ◽  
Vol 22 (12) ◽  
pp. 1585-1592 ◽  
Author(s):  
A. Noyola ◽  
B. Capdeville ◽  
H. Roques

2004 ◽  
Vol 93 (3) ◽  
pp. 241-247 ◽  
Author(s):  
A. Gangagni Rao ◽  
G. Venkata Naidu ◽  
K. Krishna Prasad ◽  
N. Chandrasekhar Rao ◽  
S. Venkata Mohan ◽  
...  

1997 ◽  
Vol 43 (10) ◽  
pp. 937-944 ◽  
Author(s):  
Jean-Claude Frigon ◽  
Jean-Guy Bisaillon ◽  
Gilles Paquette ◽  
Réjean Beaudet

Leachate from a municipal landfill site was treated in a laboratory using fixed-film cultures under anaerobic conditions. Serum-bottle cultures were used for optimization of the growth parameters. The reduction of the chemical oxygen demand (COD) of the leachate was faster at 29 °C compared with lower temperatures. Gradual acclimation of the microbial population to temperatures as low as 4 °C considerably increased the rate of COD removal at these temperatures. Addition of supplements to the leachate was not needed and it was not necessary to adjust the pH (5.9) for optimal COD reduction. Continuously fed reactors were also used to treat the leachate. The maximum organic loading rate of the reactor at 22 °C to obtain 85% COD removal was 2.1 kg COD∙m−3∙day−1, which corresponded to an hydraulic retention time of 1.5 days. After treatment under these conditions, the toxicity (Microtox method) of the leachate was completely eliminated and the required quality standards were met for iron, oil and grease, and phenols. The fermentative microorganisms in the biofilm of the reactor were evaluated to 4.6 × 107cells∙cm−2and identified as Streptococcus gallinarum, Clostridium glycolicum, Clostridium bifermentans or sadallii, Citrobacter amalonaticus, Bacteroides capillosus, and Eubacterium sp.Key words: anaerobic treatment, landfill, leachate, growth parameters, fixed-film reactor, microbiology.


1983 ◽  
Vol 15 (8-9) ◽  
pp. 305-308 ◽  
Author(s):  
M S Salkinoja-Salonen ◽  
E.-J Nyns ◽  
P M Sutton ◽  
L van den Berg ◽  
A D Wheatley
Keyword(s):  

1989 ◽  
Vol 21 (4-5) ◽  
pp. 87-95
Author(s):  
J. De Santis ◽  
A. A. Friedman

Overloaded anaerobic treatment systems are characterized by high concentrations of volatile fatty acids and molecular hydrogen and poor conversion of primary substrates to methane. Previous experiments with fixed–film reactors indicated that operation with reduced headspace pressures enhanced anaerobic treatment. For these studies, four suspended culture, anaerobic reactors were operated with headspace pressures maintained between 0.5 and 1.0 atm and a solids retention time of 15 days. For lightly loaded systems (0.4 g SCOD/g VSS-day) vacuum operation provided minor treatment improvements. For shock organic loads, vacuum operation proved to be more stable and to support quicker recovery from upset conditions. Based on these studies and a companion set of bioassay tests, it was concluded that: (a) a loading rate of about 1.0 g SCOD/g VSS-day represents a practical loading limit for successful anaerobic treatment, (b) a headspace pressure of approximately 0.75 atm appears to be an optimum operating pressure for anaerobic systems and (c) simple modification to existing systems may provide relief for organically overloaded systems.


1994 ◽  
Vol 29 (10-11) ◽  
pp. 61-67 ◽  
Author(s):  
M. Fruhen ◽  
K. Böcker ◽  
S. Eidens ◽  
D. Haaf ◽  
M. Liebeskind ◽  
...  

The objective of this study is to investigate to what extent the nitrification capacity of a pilot-plant fixed-film reactor changes during extensive periods of nutrient supply deficiency. The examined pilot-plant was an upflow reactor filled with swelling clay of medium grain size (6 to 8 mm). The experiments revealed that the maximum nitrification rate remained practically constant during the first weeks after the onset of unregulated ammonium supply. The capacity declined slowly, dropping to approximately 66% of the initial capacity after about ten weeks. Still ammonium peaks of up to 8 mg/l were readily nitrified throughout the entire period of the experiment. The reduction in nitrification capacity during the observation period did not result from decay processes of biomass but from the reactor becoming blocked and thus hampering transfer processes. It could be observed that the detached organisms attached again further up. This semi-industrial project demonstrated that a plug-flow fixed-film reactor can be used as effective means of tertiary nitrification.


2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 726.2-727
Author(s):  
S. Erdes ◽  
V. Mazurov ◽  
T. Dubinina ◽  
I. Gaydukova ◽  
A. Kundzer ◽  
...  

Background:According to previous studies, the effectiveness of interleukin-17 (IL-17) inhibitors was higher in anti-TNF-naïve patients with ankylosing spondylitis (AS) [1,2]. Netakimab (NTK) is a humanized anti-IL-17A antibody approved for the treatment of AS, psoriatic arthritis, moderate-to-severe plaque psoriasis in Russia and Belarus.Objectives:To compare the efficacy of NTK in anti-TNF-naïve patients with anti-TNF-experienced patients with active AS at week 16 of therapy.Methods:ASTERA (NCT03447704) is an ongoing phase 3 placebo (PBO)-controlled clinical study, aimed at evaluating NTK efficacy in AS [3]. 228 adult patients with active AS (BASDAI ≥ 4) were randomly assigned (1:1) to receive 120 mg NTK or PBO subcutaneously at week 0,1,2 and then q2w. This analysis includes 112 patients in NTK group. Efficacy endpoints included ASAS20/40, ASAS5/6 and ASAS partial remission (PR) at week 16 of therapy.Results:28 (25.0%) of 112 patients in NTK group had previous inadequate response/intolerance to anti-TNF (anti-TNF-IR): 24 (21.4%) – one anti-TNF, and 4 (3.6%) – two anti-TNF. 84 (75.0%) patients were TNF-naive. Achievement of ASAS criteria response at week 16 was similar in both groups (Table 1).Table 1.Efficacy of NTK at week 16ParameterTNF-naïve (n = 84)anti-TNF-IR (n = 28)p-value*ASAS20, n (%)52 (61.9%)17 (60.7%)0.91ASAS40, n (%)35 (41.7%)11 (39.3%)0.82ASAS5/6, n (%)39 (46.4%)11 (39.3%)0.51ASAS(PR), n (%)15 (17.9%) 4 (14.3%)0.78*- Fisher’s exact testConclusion:NTK 120 mg provided sustained improvements in signs and symptoms of AS in anti-TNF-naive and anti-TNF-IR patients at 16 weeks of therapy.References:[1]Blair HA, Dhillon S. Secukinumab: A Review in Ankylosing Spondylitis. Drugs. 2016;76(10):1023-30.[2]Dougados M, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176-185.[3]Mazurov VI, et al. Efficacy and safety of Netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Nauchno-Practicheskaya Revmatologia=Rheumatology Science and Practice. 2020;58 (4):376–386 (In Russ).Acknowledgements:This study was sponsored by JSC BIOCAD.Disclosure of Interests:Shandor Erdes: None declared, V Mazurov: None declared, Tatiana Dubinina: None declared, Inna Gaydukova Speakers bureau: Abbvie, Biocad, Eli Lilly, MSD, Novartis, Pfizer, Sandoz, Alena Kundzer: None declared, Nikolaj Soroka: None declared, Anna Eremeeva Employee of: Biocad


Sign in / Sign up

Export Citation Format

Share Document